Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Public Private Partnerships at the NIH; The Biomarkers Consortium (BC) A PPP managed by FNIH Partners are NIH, FDA, CMS, and private industry Barbara B. Mittleman, M.D. Director, NIH PPP Program Bioinformatics Forum March 4, 2009 BC Mission The Biomarkers Consortium endeavors to discover, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics. Precompetitive Consortium Biomarkers Consortium Partners Public Private NIH FDA CMS PhRMA / BIO Industry/ individual companies Non-Profit Patient Advocacy Groups and Professional Societies Universities FNIH FNIH FNIH : 501(c)(3) charitable foundation i.e., NOT the government! Chartered by Congress in 1990 Incorporated in 1996 Mission, per Congress, is to support the mission of the NIH Managing partner of the BC BC Structure Executive Committee SC SC SC project project project project project project project SC project Governance Structure Executive Committee (15 members) Steering Committees decision-making: advise FNIH Board on financial commitments 3 NIH, 3 FDA, 3 pharmaceutical industry, 1 CMS, 1 biotech/diagnostics/imaging industry, 1 public, 3 (non-voting) FNIH Content area focused : Neuroscience, Metabolic Diseases, Oncology, Inflammation and Immunity Identify and oversee specific project activities Project Teams Implement projects Intellectual Property Pre-competitive focus: BC strives not to generate new IP, although it might happen Existing IP coming into PPPs will be protected New IP will be handled in accordance with Federal law and BC/PT specific agreements Data/Sample Sharing and Access Must comply with human subjects protections Informed consents must be consistent with the BC activities if samples are to be used or distributed Precompetitive structure broad public availability of data and samples, generation of public resources Confidentiality Pre-existing data, samples, and activities contributed to BC activities will be considered to be confidential if the donor requests (subject to antitrust review) Confidentiality Agreements will be executed, as needed No more than the minimum needed for Consortium activities should be shared with project Aim is to maximize public availability, in accordance with the project plan Conflict of Interest FNIH is not NIH For NIH employees, these are official duty activities FNIH rules require disclosure and reporting Intention is to optimize fairness and openness. Antitrust Issues Industry collaborations with more than a single company may expose participants to antitrust liability The Federal government is not liable Partnering with the government does not immunize private partners against antitrust liability BC rules comply with Federal antitrust law BC Grantee/Contractor Selection FNIH is not NIH Awards are FNIH awards, not NIH awards FNIH/BC Conflict of Interest and Confidentiality policies apply Solicitation and independent scientific review conducted by FNIH Responders, awardees, and reviewers may be BC members or not Initial Projects 1) FDG-PET: qualification studies Lymphoma non-small cell lung cancer 2) Adiponectin in Type 2 Diabetes data pooling to assess utility of adiponectin as a marker of PPAR against responsiveness Initial Projects 3) PET ligand development: developing and qualifying PET tools for drug development 4) Circulating Tumor Cell identification 5) Other projects in development in OA, depression, etc…. Important Links NIH PPP Program http://ppp.od.nih.gov FNIH www.fnih.org The Biomarkers Consortium www.biomarkersconsortium.org